17 April 2019
Chaim Hurvitz, New Board of Directors Member
Chaim Hurvitz has joined Genoscience Pharma Board of Directors: high-level expertise will help develop GNS561…
Read More
10 December 2018
Most Innovative European Biotech SME for 2018
Company receives award in healthcare category for cancer therapy in clinical development with an action…
Read More
9 November 2018
Raphaël Rodriguez: Winner 2019 Tetrahydron Young Investigator Award
Genoscience Pharma is proud to announce that one of the members of its Scientific Advisory…
Read More
October 5, 2018
Extension to US of GNS561 Clinical Trial
Genoscience Pharma Extends to US its Clinical Trial in Patients with Advanced Liver Cancers …
Read More
June 4, 2018
S.A.B. Meeting in Chicago, during ASCO 2018
Scientific Advisory Board Meeting during ASCO 2018 Chicago, USA, June 4, 2018 — During…
Read More
May 22, 2018
Extension to France of GN561 Clinical trial
Genoscience Pharma Extends its GNS561 Clinical Trial to France Enrollment is open for patients with…
Read More
April 5, 2018
First-in-human Dosing of GNS561 in Liver Cancer Patients
First-in-human Dosing of GNS561 in Patients with Advanced Liver Cancer at the Jules Bordet Institute,…
Read More
December 6, 2017
GNS561 Gets US FDA IND Approval in Liver Cancer
Genoscience Pharma Receives FDA Approval for Phase Ib/IIa Study of GNS561 in Liver Cancer …
Read More
February 24, 2016
Four New Members in Our Directory Board
Marseille, France - February 24, 2016 – Genoscience Pharma today announces the arrival of four new…
Read More
February 6, 2012
BL-8030 worldwide License Agreement with BioLineRx
RFS Pharma and Genoscience Pharma enter Worldwide License Agreement with BioLineRx to develop and commercialize Hepatitis…
Read More
